Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Glantz SA. Estimation of 1-Year Changes in Medicaid Expenditures Associated With Reducing Cigarette Smoking Prevalence by 1%. JAMA Netw Open. 2019;2(4):e192307. doi:10.1001/jamanetworkopen.2019.2307
What are the expected changes to Medicaid costs the following year associated with reducing absolute cigarette smoking prevalence in each state by 1%?
This economic evaluation found that, based on observed short-run elasticity between changes in smoking and health care expenditures, estimated Medicaid savings in the year following a 1% reduction of smoking prevalence would total $2.5 billion, with median state savings of $26 million.
Reducing cigarette smoking could contribute to lowering Medicaid costs in the short run.
Reducing smoking is associated with a reduction in health care costs, including in the short run. Medicaid recipients smoke at higher rates than the general population, which suggests that investments to reduce smoking in this population would reduce short-run Medicaid costs.
To estimate the short-run (1-year) change in health care expenditure associated with a 1% decrease in absolute smoking prevalence in all US states.
Design, Setting, and Participants
Economic evaluation based on state Medicaid expenditures and the elasticity between changes in smoking prevalence and health care costs. Data sources were the 2017 Behavioral Risk Factors Surveillance System, 2017 National Health Interview Survey, and Kaiser Family Foundation Total Medicaid Spending for fiscal year 2017. Analysis was conducted in 2018. Participants were all people receiving Medicaid in all US states and the District of Columbia.
Main Outcomes and Measures
Short-run (1-year) change in health care costs.
Reducing absolute smoking prevalence by 1% in each state was associated with substantial Medicaid savings the following year, totaling $2.5 billion (in 2017 dollars). Each state saved a median (interquartile range) of $26 million ($10 million to $52 million).
Conclusions and Relevance
Effective efforts to reducing smoking could be a cost-effective way to reduce Medicaid costs in the short run.
In fiscal year 2017, total Medicaid costs were $577 billion.1 It is widely accepted that reducing smoking is associated with a reduction in health care costs, but the implicit assumption has been that it takes years to see these savings. While this may be true for some diseases, notably cancer, other risks change quickly in response to changes in smoking behavior, including myocardial infarction, lung disease, and complications of pregnancy. Medicaid recipients smoke at higher rates than the general population; in 2017, 24.5% of adult Medicaid recipients (aged ≥18 years) smoked cigarettes compared with 14.0% of all adults,2 suggesting that investments to reduce smoking in this population could be associated with a reduction in Medicaid costs in the short run.3
This article reports the results of a secondary data analysis using large deidentified data sets, which is not considered human subjects research and is therefore exempt from review according to the University of California, San Francisco, institutional review board. Reporting of the study followed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) reporting guideline. The analysis was conducted in 2018.
Participants of the study were people receiving Medicaid in all US states and the District of Columbia. Data sources were the 2017 Behavioral Risk Factors Surveillance System, 2017 National Health Interview Survey (NHIS), and Kaiser Family Foundation Total Medicaid Spending for fiscal year 2017. The 2017 Behavioral Risk Factors Surveillance System provides smoking prevalence for each state4 but does not provide data on smoking prevalence for people receiving Medicaid. In contrast, the 2017 NHIS does identify Medicaid recipients,5 defined as persons who do not have private coverage, but who have Medicaid or other state-sponsored health plans including the Children’s Health Insurance Program. The NHIS does not provide state-level data; it aggregates the states into 4 major census regions (Northeast, Midwest, South, and West) (Table 1).
Adult Medicaid recipients smoke (defined as persons who had smoked ≥100 cigarettes during their lifetime and now smoked cigarettes either every day or some days) at higher rates than the general population. In addition, there are differences in cigarette smoking by Medicaid recipients across states as well as differences in Medicaid eligibility, benefits, and medical costs.
We used the NHIS to estimate the cigarette smoking prevalence among the general population and Medicaid recipients in each census region accounting for person-level weights (Table 1), then computed the ratio of these 2 prevalences (Table 1). We then multiplied the Behavioral Risk Factors Surveillance System prevalence estimates for each state (Table 2, third column) in each of the 4 census regions (Table 2, second column) by the corresponding ratio (Table 2, fifth column) for states in that census region to estimate cigarette smoking prevalence among Medicaid recipients in each state (Table 2, fourth column).
Lightwood and Glantz6 quantified short-run changes in health care costs the year after changes in smoking behavior and found that 1% relative reductions in current smoking prevalence and mean packs smoked per current smoker are associated with mean (SE) reductions of 0.118% (0.026%) and 0.108% (0.025%) in per capita health care expenditure (elasticities). For this analysis, we concentrate on changes in prevalence. (Given the similar elasticity for changes in consumption per smoker, the results would be similar for changes in consumption per smoker. One could also estimate the effects of simultaneous changes in both variables by adding the effects of the 2 changes.)
To apply the 0.118 elasticity between changes in cigarette smoking prevalence and changes in health care expenditures the following year, we need to compute the relative decrease in prevalence that corresponds to a 1% decrease in absolute prevalence in each state. Dividing the 1% absolute prevalence decrease by the estimated Medicaid prevalence (Table 2, fourth column) yields the corresponding relative change in prevalence (Table 2, sixth column).
Finally, we multiplied the state Medicaid cost for 2017 reported by the Kaiser Family Foundation1 (Table 2, seventh column) by the 0.118 elasticity and the relative change in prevalence (Table 2, sixth column) to obtain the estimated Medicaid savings in each state (Table 2, eighth column) if they lowered absolute cigarette smoking prevalence by 1%.
Table 2 shows that reducing absolute smoking prevalence by 1% in each state was associated with substantial Medicaid savings the following year, totaling $2.5 billion (in 2017 dollars). The median (interquartile range) state savings was $26 million ($10 million to $52 million).
The results of this study indicate that investments in policies to motivate and assist Medicaid recipients to stop smoking may yield substantial savings in short-term medical costs.
These estimates are based on cigarette smoking only,6 and the use of noncigarette tobacco products is increasing. While 14.0% of adults were current cigarette smokers in 2017, 19.3% used some tobacco product.2 To the extent that tobacco control programs are associated with reduced use of these other tobacco products, there could be additional savings. This analysis is focused on reductions in prevalence; reductions in consumption by continuing smokers may also be followed by reductions in health care costs.6 Because some of the risks of smoking, such as cancer, emerge more slowly over time, these medical cost savings would likely grow with time.
The fact that the NHIS data are only available by region but are applied to individual states introduces uncertainty, as different states have different age, racial, and sex distributions. Unfortunately, more granular data are not available. Many Medicaid recipients are children (and so their health costs are included in Table 2, seventh column), but the estimates of Medicaid savings are based only on adult smoking. Because the elasticity estimates are based on aggregate measures of population characteristics, these estimates reflect all the health care expenditures associated with smoking that arise in a population, which include at least some of the indirect health effects on smokers and of secondhand and thirdhand smoking exposure to nonsmokers, including children.6
In addition to the benefits in terms of improved health, this study suggests that reducing smoking among Medicaid recipients may result in substantial savings to the Medicaid program, which would release these funds for other state and federal priorities.
Accepted for Publication: February 26, 2019.
Published: April 12, 2019. doi:10.1001/jamanetworkopen.2019.2307
Correction: This article was corrected on July 31, 2019, to fix errors in estimated savings in the Key Points, Abstract, Results section, and Table 2.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Glantz SA. JAMA Network Open.
Corresponding Author: Stanton A. Glantz, PhD, Center for Tobacco Control Research and Education, Philip R. Lee Institute for Health Policy Studies, Department of Medicine, University of California, San Francisco, San Francisco, CA 94143-1390 (email@example.com).
Author Contributions: Dr Glantz had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Glantz.
Acquisition, analysis, or interpretation of data: Glantz.
Drafting of the manuscript: Glantz.
Critical revision of the manuscript for important intellectual content: Glantz.
Statistical analysis: Glantz.
Obtained funding: Glantz.
Administrative, technical, or material support: Glantz.
Conflict of Interest Disclosures: None reported.
Funding/Support: This study was supported by grant R01DA043950 from the National Institute on Drug Abuse.
Role of the Funder/Sponsor: The funding agency had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: James Lightwood, PhD, University of California, San Francisco, provided feedback on this article; he was not compensated for this advice.
Meeting Presentation: This work was presented as an abstract at the 2019 Society for Research on Nicotine and Tobacco Annual Meeting; February 23, 2019; San Francisco, California.
Create a personal account or sign in to: